SCHEMBL6554011

SCHEMBL6554011

COC(=O)c1ncn([C@@H]2O[C@H](CO)[C@H]3OC(C)(C)O[C@H]32)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ GLA P06280 1/20 0.46
▸ EIF4E P06730 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ TOP1 P11387 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ ADORA1 P30542 1/20 0.46
▸ THPO P40225 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ PI4KA P42356 1/20 0.45
▸ PI4K2B Q8TCG2 1/20 0.45
▸ PI4K2A Q9BTU6 1/20 0.45
▸ PI4KB Q9UBF8 1/20 0.45
▸ ADRB3 P13945 1/20 0.45
▸ TMEM97 Q5BJF2 1/20 0.45
▸ HRH3 Q9Y5N1 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.44
▸ PNP P00491 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13058163 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL12879149 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL3762066 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL6839692 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL12892430 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL24024691 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL7377274 0.86 LMNA (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL12879147 0.86 LMNA (0.42) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL12879155 0.83 LMNA (0.41) LMNAALDH1A1SMN1; SMN2GLAEIF4E
SCHEMBL13606971 0.82 PNP (0.63) LMNAALDH1A1SMN1; SMN2GLAEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1485396-A2 NUCLEOSIDE 5'-MONOPHOSPHATE MIMICS AND THEIR PRODRUGS Biota, Inc. (US) 2004-12-15 — — EP disclosed
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs BIOTA HOLDINGS LIMITED (AU) 2004-02-05 — — US disclosed
WO-2003073989-A2 NUCLEOSIDE 5'-MONOPHOSPHATE MIMICS AND THEIR PRODRUGS BIOTA, INC. (US) 2003-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs MTAP, ENTPD5, PNP LMNA 4394/4885ALDH1A1 2159/4885SMN1; SMN2 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback